{"id":"W2605943665","doi":"10.1182/blood.v128.22.1218.1218","title":"Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Cégep de l'Outaouais; Jewish General Hospital","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Adverse effect; Refractory (planetary science); Phases of clinical research; Lymphoma; Clinical endpoint; Oncology; Regimen; Salvage therapy; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":{"n_in":0,"stratum":"aff_core","weight":5595.2375,"opus":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"Phase 2 clinical trial of duvelisib in lymphoma; a clinical efficacy question."},"gpt":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"This reports a clinical trial of lymphoma treatment, not research itself."},"grok":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"Phase 2 clinical trial of duvelisib in indolent lymphoma; therapeutic efficacy, not research practice."}},"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001548452,0.0006620766,0.001208516,0.0003154643,0.0002585361,0.0006645616,0.0005555702,0.0006679148,0.002377949],"category_scores_gemma":[0.0005922522,0.0003541837,0.0005612709,0.0002479375,0.0004118283,0.0004446202,0.00027558,0.001553366,0.0004194221],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004553137,"about_ca_system_score_gemma":0.0008910613,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000504827,"about_ca_topic_score_gemma":0.001403866,"domain_scores_codex":[0.9997488,0.0001232143,0.00001601313,0.00003698565,0.00003030739,0.00004477224],"domain_scores_gemma":[0.999525,0.00009223029,0.00008497341,0.00003838539,0.00003869435,0.0002208162],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4965918,0.0951582,0.02335466,0.002936333,0.001865371,0.0007496899,0.0005210616,0.002351453,0.164074,0.0005118118,0.008174906,0.2037106],"study_design_scores_gemma":[0.4944086,0.4547457,0.03070054,0.00006919734,0.0005279916,0.0009732111,0.0001019939,0.001512592,0.009647254,0.000171345,0.007098726,0.00004277366],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925445,0.002482703,0.0005095721,0.0002590648,0.00006393649,0.001657148,0.0007750848,0.0001131039,0.001594994],"genre_scores_gemma":[0.9904023,0.001387428,0.001523692,0.0007197037,0.00009861703,0.001741234,0.001907567,0.00002531265,0.002194179],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002377949,"threshold_uncertainty_score":0,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02460202195842038,"score_gpt":0.3463210955347562,"score_spread":0.3217190735763358,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}